Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA Outlines Streamlined Development Path For Targeted Therapies

Executive Summary

But reminds sponsors that more trials could be ordered post-approval, which may be important in face of evidence that tissue-agnostic cancer therapies are not always equally effective.

You may also be interested in...



US FDA Seeks Ways To Prevent Non-Responders From Sinking Tissue-Agnostic Indications

Agency officials and oncologists debate considerations where a data package overwhelms non-responders in favor of a tissue-agnostic indication.

Vitrakvi, Daurismo Approvals Put US FDA On Brink Of Another Record

New oncologics bring CDER’s novel agent approvals count to 53 for the year.

Antibiotic Development Question: Should A Phage Library Equal One Application?

FDA may have to take a personalized medicine approach when deciding how to classify a phage bank used to create the treatments.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1127674

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel